跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 2,020 条关于
“KEYNOTE-522”
全部
2,020
临床试验
1,067
药物
495
机构
7
资讯
451
2年前
Pembrolizumab Plus Chemotherapy Improves Overall Survival in Early-Stage TNBC
去年
Cleveland Clinic Reports Real-World Outcomes of KEYNOTE-522 Regimen in Triple-Negative Breast Cancer Treatment
2年前
Keytruda Demonstrates Significant Overall Survival Benefit in Early-Stage TNBC
去年
Keynote-522 Trial Demonstrates Overall Survival Benefit with Pembrolizumab in Triple-Negative Breast Cancer
去年
Real-World Data Shows Improved Responses with Pembrolizumab/Chemotherapy in Early-Stage TNBC
2年前
Pembrolizumab Plus Chemotherapy Improves Overall Survival in Early-Stage TNBC
去年
Pembrolizumab Plus Chemotherapy Improves Overall Survival in Early-Stage TNBC
2年前
Pembrolizumab Plus Chemotherapy Improves Overall Survival in Early TNBC
2年前
Pembrolizumab Plus Chemotherapy Demonstrates Overall Survival Benefit in Early TNBC
2年前
Pembrolizumab Plus Chemotherapy Improves Overall Survival in High-Risk Early-Stage TNBC
第 1 页,共 46 页
上一页
下一页